Pretax income is the income that a company earns before paying income taxes. Sarepta Therapeutics's pretax income for the
three
months ended in Dec. 2023 was $40 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-520 Mil.
Sarepta Therapeutics's pretax margin was 10.17%.
During the past 13 years, Sarepta Therapeutics's highest Pretax Margin was -31.46%. The lowest was -17560.26%. And the median was -111.43%.
Sarepta Therapeutics Pre-Tax Income Historical Data
The historical data trend for Sarepta Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sarepta Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Sarepta Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Pre-Tax Income falls into.
Sarepta Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Sarepta Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-520 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (NAS:SRPT) Pre-Tax Income Explanation
Sarepta Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Sarepta Therapeutics's highest Pretax Margin was -31.46%. The lowest was -17560.26%. And the median was -111.43%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Sarepta Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarepta Therapeutics (Sarepta Therapeutics) Business Description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRPT has been successfully added to your 